Abstract: About 130-170 million people, is estimated to be infected with the hepatitis C virus (HCV). Chronic HCV infection is one of the leading causes of liver- related death and in many countries it is the primaryreason for having a liver transplant. The main aim of antiviral treatment is to eradicate the virus. Until a few years ago the only treatment strategy was based on the combination of pegylated interferon and ribavirin (PEG/RBV). However, in genotypes 1 and 4 the rates of viral response did not surpass 50%, reaching up to 80% in the rest. In 2013 and 2014 approval were given for the direct acting antiviral agents (DAA), sovaldi and harvoni, serially, for treatment of HCV patients. These DAA created a new scenario: shorter therapies, less toxicity (free of PEG/RBV), increased rates of SVR (even up to 100%), with pan-genomic properties and excellent tolerance.This has enabled their almost generalised applicability in all patients. Recent years, FDA approved a series of new more effective DAA, However, it should be noted that most of the scientific evidence available is based on expert opinion, case-control series, cohort studies and phase 2 and 3 trials, some with a reduced number of patients and select groups. Few data are currently available about the use of these drugs in daily clinical practice, particularly in relation to the appearance of side effects and interactions with other drugs, or their use in special populations or persons with the less common genotypes. This situation suggests the need for the generalised implementation of registries of patients receiving antiviral therapy. In a clinical study carried out in china, 500 HCV patients received recent DAA treatment. The results indicate that...

Key words: Hepatitis C; Treatment; Direct acting antiviral agents; Chinese Patients; Outcome